Table 3.
The prognostic value of FcγRIIA and FcγRIIIA polymorphisms for PFS in patients with metastatic GC: univariate and multivariate analyses
| Set A (n=42)
|
Set B (n=68)
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median PFS (months) | Univariate
|
Multivariate
|
Median PFS (months) | Univariate
|
Multivariate
|
|||||
| Hazard ratio (95% CI) | P-value | Adjusted hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | Adjusted hazard ratio (95% CI) | P-value | |||
| General | 7.23 | 5.27 | ||||||||
| FcγRIIA polymorphism | 0.02 | 0.001 | 0.83 | 0.78 | ||||||
| H/R or R/R | 4.93 | 1 (reference) | 1 (reference) | 5.67 | 1 (reference) | 1 (reference) | ||||
| H/H | 11.7 | 0.36 (0.16–0.82) | 0.18 (0.07–0.48) | 4.60 | 1.06 (0.61–1.86) | 0.91 (0.50–1.69) | ||||
| FcγRIIIA polymorphism | 0.12 | 0.09 | 0.96 | 0.94 | ||||||
| F/V or F/F | 6.87 | 1 (reference) | 1 (reference) | 6.07 | 1 (reference) | 1 (reference) | ||||
| V/V | 0.20 (0.03–1.49) | 0.15 (0.02–1.31) | 2.93 | 1.02 (0.50–2.06) | 0.97 (0.45–2.09) | |||||
| FcγRIIA and IIIA | − | 0.004 | <0.001 | 0.62 | 0.94 | |||||
| Others | 4.33 | 1 (reference) | 1 (reference) | 5.67 | 1 (reference) | 1 (reference) | ||||
| H/H or V/V | 15.93 | 0.29 (0.13–0.67) | 0.17 (0.07–0.45) | 4.60 | 1.15 (0.66–2.03) | 1.03 (0.56–1.90) | ||||
Notes: Set A: patients with Her-2-positive GC who received trastuzumab combined with chemotherapy as the first-line treatment. Set B: patients with Her-2–negative GC who received chemotherapy only as the first-line treatment. Multivariate analysis for the prognostic value of FcγRIIA and FcγRIIIA polymorphisms was adjusted by age (<02/≥52 years), gender (male/female), ECOG score (0/1), degree of differentiation (well-differentiated adenocarcinoma/moderately differentiated adenocarcinoma/poorly differentiated/signet ring cell carcinoma/mucinous adenocarcinoma), and Lauren classification (intestinal type/diffuse type/mixed type).
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FcγR, Fc γ receptor; GC, gastric cancer; ORR, objective response ratio; PFS, progression-free survival.